Canadian Critical Minerals Generates USD$140,000 in Revenue from Bull River Mine
Calgary, Alberta--(Newsfile Corp. - May 21, 2025) - Canadian Critical Minerals Inc. (TSXV: CCMI) (OTCQB: RIINF) ("CCMI" or the"Company") is pleased to report revenues for the Company from the sale of stockpiled copper, gold and silver mineralized material at the Bull River Mine (" BRM") project near Cranbrook, BC. During the month of April 2025, the Company trucked 429 dry metric tonnes (" dmt") of sorted mineralized material to New Afton and the Company received a provisional payment of approximately USD$144,000 for the April 2025 shipments. The mineralized material sent to New Afton graded 2.87% Cu, 1.97 g/t Au and 21.0 g/t Ag.
Road restrictions imposed by the Ministry of Transportation and Infrastructure of British Columbia on March 7, 2025 were removed in the last week of April 2025 resulting in the Company's ability to resume trucking to New Afton. During May 2025, the Company will continue to truck higher-grade mineralized copper, gold and silver material to New Afton that was stockpiled at the mine during road restrictions as well as new material that is being processed through the ore sorter in May 2025.
About Canadian Critical Minerals Inc.
CCMI is a mining company primarily focused on copper production assets in Canada. CCMI's main asset is the 100% owned Bull River Mine project (150 million lbs of copper) near Cranbrook, British Columbia which has a Mineral Resource containing copper, gold and silver. CCMI also owns a 10% interest in XXIX Metal Corp. which holds a 100% interest in the Thierry copper project near Pickle Lake, Ontario and a 100% interest in the Opemiska copper project near Chapais-Chibougamau, Quebec.
Caution Regarding Forward-Looking Information
This news release includes certain information that may constitute "forward-looking information" under applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, future work programs and objectives and expected results from such work programs. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks.
Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information and the risks identified in the Company's continuous disclosure record. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
39 minutes ago
- CTV News
GECDSB approves budget deficit for upcoming school year
Trustees for the Greater Essex County District School Board approved a nearly $1 million deficit for the upcoming fiscal year. June 17, 2025. (Robert Lothian/CTV News Windsor) Trustees for the Greater Essex County District School Board approved a nearly $1 million deficit for the upcoming fiscal year, pointing to underfunding and declining enrolment. Members received a grim snapshot of the board's finances on Tuesday afternoon before approving the 2025-2026 budget at its regular meeting. Shelley Armstrong, the board's superintendent of business and treasurer, outlined the pressures highlighted by 'inadequate' funding from the Ministry of Education. 'There are several areas where the board experiences funding deficits because the funding allocation is inadequate to support the current expense structure,' Armstrong told trustees. The budget outlines a preliminary deficit of $988,924 for the upcoming school year, but Armstrong noted that could change depending on enrolment. Cuts and reductions were previously outlined in the board's multi-year financial recovery plan approved in November. Under the changes, the board will cut some positions, and eliminate or phase out the International Baccalaureate program at multiple schools. The Rise Program, a special education program providing individualized programming for students, will also be scaled back. Several trustees stated the deficit would be erased if there was sufficient annual funding from the province. 'What we have is an inadequate funding model that leaves our board and every other board across the province at risk for decisions that are made at tables that we don't even have a seat at,' said trustee Ron Le Clair. Trustees plan to send a letter to the provincial and federal governments highlighting desired changes and funding needs. However, Mario Spagnuolo, president of the Elementary Teachers Federation of Ontario Greater Essex County local, told CTV News more action is needed. 'This is not a spending problem, this is a funding problem,' Spagnuolo said. 'You have trustees seeing that across the province of Ontario, you have MPPs across the province ignoring that, so we need to work together as a community to say we need to improve our schools.' Another factor in the deficit is lagging enrolment levels based on current registration. The board currently projects to have about 954 fewer students, but that could still increase depending on registration levels. As part of its multi-year financial plan, the board must reach a balanced budget by the 2026-2027 school year. 'The budget process has always been difficult for as long as I've been a trustee because there are huge gaps in the funding that we have no control over,' Board chairperson Gale Hatfield told CTV News. If the board fails to meet budget targets, it risks the province taking action to implement measures of its own. Hatfield said she was 'confident' they will meet the necessary steps to avoid such a case. 'The experience that other boards have had with supervision is that the ministry comes in and makes decisions without any consideration of local conditions or local needs of the community, and so I don't see how that would serve our students in the best way,' Hatfield said. When asked about the potential for future cuts to meet the targets, Armstrong said it's not off the table. 'Will there be further reductions coming? I would say it's fairly certain yes, we're going to have to do some more work,' Armstrong added. The budget is now pending approval by the education minister.
CTV News
39 minutes ago
- CTV News
City taps brakes on parking lot to housing plan in OEV— but full speed ahead in SoHo
Municipal parking lot at 199 Ridout St. in London as seen on June 17, 2025. (Daryl Newcombe/CTV News London) Three municipal parking lots remain candidates for redevelopment into housing, but the next steps will occur at two different paces. On Tuesday, the Strategic Priorities and Policy Committee (SPPC) heard from stakeholders in the Old East Village (OEV) who want public consultation and further discussion with key stakeholders before deciding if most of the lot at 641 Queens Ave. should be redeveloped into a mix of low and medium-density housing. Kevin Morrison of the OEV Business Improvement Area told the committee, 'The BIA supports more affordable housing, that's not the question. However, how we get there is what really matters. If we're going to do this, we need to do it right.' Morrison asked the committee to defer any substantial decisions about 641 Queens Ave. until after public consultation this summer. However, Coun. Sam Trosow said he was satisfied with proceeding to next steps before completing the first round of public consultation, 'Build into this process, which is going to take a long time, many different decision points with consultation.' Morrison expressed other concerns including if the remaining parking lot would be large enough to accommodate tour buses visiting the Banting House National Historic Site, and that the lot was deemed 'underutilized' because daily usage of spots has recently been about 51 per cent. He argued that as revitalization of the business district continues, commercial vacancies will decline and the drive up the demand for parking. Deputy Mayor Shawn Lewis agreed that more time is needed to assess the future parking requirements, 'A 50 per cent more or less parking utilization doesn't seem like a very high amount, but I also appreciate the comment that there's a 40 per cent commercial vacancy right now.' The assessment of municipal parking lots for developability into housing was launched by Mayor Josh Morgan in early 2024 by utilizing his Strong-Mayor Powers. LONDON - QUEENS AVE - PLAN - JUNE 2025 Preliminary development plan for parking lot at 641 Queens Ave. 'It's actually quite a complicated site, as you can see with the land assembly, and it's probably relatively restricted in the amount of density that you could put in there,' Morgan told council colleagues. The next steps to make the parking lot shovel ready for developers would include an archeological investigation, land assembly, traffic impact study and geotechnical work. Staff estimate that work would cost $555,000 to complete. SPPC members voted to defer a decision to make the parking lot shovel ready until the end of this year, to allow time for more consultation and to determines if there is even going to be interest from developers. 'Let's slow this down,' the mayor told CTV News after the meeting. 'Let's take some time to consult with the community more and let's do a Request for Expressions of Interest to see if there's even an interest in developing that lot.' However, it remains full speed ahead for the two municipal lots in the SoHo neighbourhood just north of the Thames River (84 Horton St. and 199 Ridout St.). Morgan expressed excitement about advancing the lots directly to a Request for Proposals for 'as-is' offers from developers by the end of 2025. Three submissions have already been made, ranging between 450 units and 600 units, with between 10 per cent and 20 per cent being affordable housing. Each proposal also includes between 300 and 330 public parking spaces. The city will seek as-is offers because soils in the area are contaminated with coal tar left behind by the London Coal Gasification Site that operated from 1850 until 1930. The mayor explained his excitement to proceed to the next step, 'We got a little more work to do because it's a contaminated site, (but) if we were able to change that into residential development, that would be phenomenal for the area.'
Cision Canada
an hour ago
- Cision Canada
Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter
NASDAQ| TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue 1 of $244.4 million, representing 39% YoY growth Delivers Record Adjusted EBITDA 1 of $49.7 million, representing 261% YoY growth Generates Annual Positive Free Cash Flow 1 of $9.9 million Sustains Strong Balance Sheet with ~$185.3 million of Cash and Debt-Free Cannabis Business 2 EDMONTON, AB, June 18, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025. "We are pleased to report an exceptional year to our shareholders, highlighted by record annual global medical net revenue 1, adjusted EBITDA 1, and positive free cash flow 1. These achievements underscore the thoughtful execution of our strategic plan, set us further apart from competitors, and strengthen our foundation for sustained and profitable growth," said Executive Chairman and Chief Executive Officer for Aurora, Miguel Martin. "Specific to Q4 2025, we ended our banner fiscal year by further strengthening our business model. International revenue more than doubled, representing 61% of global medical cannabis net revenue 1. Plant propagation also increased significantly as we benefited from peak seasonality along with organic expansion. These top-line gains were complemented by a sharp year over year increase in adjusted EBITDA 1 profitability and the third quarter of positive free cash flow 1 generation." concluded Mr. Martin. _________________________________ 1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures. 2 Aurora's only remaining debt is non-recourse debt of $61.7 million relating to Bevo Farms Ltd as detailed in the March 31, 2025 Financial Statements. Fourth Quarter 2025 Highlights (Unless otherwise stated, comparisons are made between fiscal Q4 2025, Q3 2025, and Q4 2024 results and are in Canadian dollars) Consolidated Revenue and Adjusted Gross Profit: Total net revenue 1 was $90.5 million, as compared to $67.4 million in the prior year period. The 34% increase from the prior year period was mainly due to 48% growth in our global medical cannabis business and 32% growth in our plant propagation business, slightly offset by lower quarterly revenue in our consumer cannabis business. Consolidated adjusted gross margin before fair value adjustments 1 was 62% in Q4 2025 and 50% in the prior year period. Adjusted gross profit before FV adjustments 1 was $54.2 million in Q4 2025 compared to $33.4 million in the prior year period, an increase of 62%. Medical Cannabis: Medical cannabis net revenue 1 was $67.8 million, a 48% increase from the prior year period, delivering 75% of Aurora's Q4 2025 consolidated net revenue 1 and 88% of adjusted gross profit before fair value adjustments 1. The increase in medical cannabis net revenue 1 of $22.1 million was primarily due to higher sales to Australia, Germany, Poland, and the UK, as well as increased revenue in Canada to insurance covered and self-paying patients. Adjusted gross margin before fair value adjustments 1 on medical cannabis net revenue 1 reached 70% for the three months ended March 31, 2025, compared to 66% in the prior year period. The adjusted gross margins before fair value adjustments 1 improved through sustainable cost reductions, higher selling prices, and improved efficiency in production operations, including sourcing for Europe from Canada. Consumer Cannabis: Aurora's consumer cannabis net revenue 1 was $8.2 million a 20% decrease compared to $10.2 million in the prior year period. The decrease was due to our continued decision to prioritize the supply of our GMP manufactured products to our high margin global medical cannabis business rather than the consumer business, which offers lower margins. Adjusted gross margin before fair value adjustments 1 on consumer cannabis net revenue 1 was 27%, an increase from 16% compared to the prior year period. The increase from the prior year period is primarily due to cost improvements resulting from spend efficiencies. Plant Propagation: Plant propagation net revenue 1 was wholly comprised of the Bevo business, and contributed $13.8 million of net revenue 1, a 32% increase compared to $10.4 million in the prior year period. The increase was a result of organic growth and expanded product offerings, both arising from increased capacity. Adjusted gross margin before fair value adjustments 1 on plant propagation revenue was 37% for Q4 2025 and 25% for the prior year period. The fluctuations in the plant propagation adjusted gross margin before fair value adjustments 1 is due to product mix with higher margin sales. Adjusted Selling, General and Administrative ("Adjusted SG&A"): Adjusted SG&A 1 was $36.7 million in Q4 2025, which excludes $5.8 million of business transformation costs. The increase compared to the prior year period relates to higher freight and logistics costs, notably from sales to Europe with the increase in sourcing from Canada and incremental costs following the acquisition of MedReleaf Australia. Net Income (Loss): Net loss from continuing operations for the three months ended March 31, 2025 was $17.2 million compared to a net loss of $20.3 million for the prior year period. The decrease in net loss of $3.0 million compared to the three months ended March 31, 2024 is comprised of a decrease in gross profit of $18.8 million and an increase in operating expenses of $3.0 million, offset with other income in the current period $10.5 million compared to other expenses of $18.7 million during the three months ended March 31, 2024. Adjusted EBITDA: Adjusted EBITDA 1 increased 619% to $16.7 million for the three months ended March 31, 2025 compared to $2.3 million for the prior year period. Fiscal Q1 2026 Expectations: Expect continued strong global cannabis revenue driven by improved performance in Canadian medical, comparable performance in consumer, offset by temporary declines in some of our international markets. Taken together, global cannabis should be slightly lower compared to Q4 2025 and is expected to improve in later quarters due to increased distribution and further innovation. Seasonally higher revenues for plant propagation as they complete their peak quarter, in line with historical seasonal trends. Margins to hold strong and we expect positive adjusted EBITDA 1 to continue, with a decline versus Q4 FY25 due to lower revenue contributions from the higher margin international markets. Free cash flow 1 is projected to remain positive, due to continued strong performance and improved operating cash use. Historical Quarterly Results: In connection with the audit of the annual consolidated financial statements as at and for the year ended March 31, 2025, the Company identified an error in inventory and cost of sales arising from intercompany profit eliminations, resulting in an overstatement of inventory and understatement of cost of sales. Additionally, the Company understated its lease liability during a period in which a rent concession was granted by the lessor. In respect of the Company's presentation of cash and cash equivalents and restricted cash, the Company determined that certain previously reported restricted cash held within its captives was accessible to the Company and therefore not restricted. The unrestricted portion has been reclassified to cash and cash equivalents. The Company has concluded that these errors are not material to any of the Company's previously-issued audited consolidated financial statements and unaudited condensed consolidated interim financial statements. Accordingly, the Company has concluded that an amendment to its previously-filed audited consolidated financial statements and unaudited condensed consolidated interim financial statements is not required. The revisions will be reflected in the comparative period of the Company's prospective condensed consolidated interim financial statements filings. There is no impact to the annual consolidated financial statements, however the comparative periods have been revised accordingly. The core balances impacted in the consolidated financial position and cash flow are: cash and cash equivalents, restricted cash, inventory and property, plant and equipment. In the consolidated statement of income (loss) the core areas impacted are: cost of sales, gross profit and net income (loss). A summary of the impact to its previously filed audited consolidated financial statements and unaudited condensed consolidated interim financial statements can be found in the historical quarterly results section of the FY25 Q4 MD&A, filed June 18, 2025 (the "MD&A"). Key Quarterly Financial Results ($ thousands, except Operational Results) Three months ended March 31, 2025 December 31, 2024 (4) $ Change % Change March 31, 2024 (3) $ Change % Change Financial Results Net revenue (1a) $90,538 $88,198 $2,340 3 % $67,411 $23,127 34 % Medical cannabis net revenue (1a) $67,776 $68,149 ($373) (1 %) $45,648 $22,128 48 % Consumer cannabis net revenue (1a) $8,166 $9,912 ($1,746) (18 %) $10,233 ($2,067) (20 %) Plant propagation revenue $13,770 $8,897 $4,873 55 % $10,416 $3,354 32 % Adjusted gross margin before FV adjustments on total net revenue (1b) 62 % 61 % N/A 1 % 50 % N/A 12 % Adjusted gross margin before FV adjustments on cannabis net revenue (1b) 65 % 63 % N/A 2 % 54 % N/A 11 % Adjusted gross margin before FV adjustments on medical cannabis net revenue (1b) 70 % 69 % N/A 1 % 66 % N/A 4 % Adjusted gross margin before FV adjustments on consumer cannabis net revenue (1b) 27 % 26 % N/A 1 % 16 % N/A 11 % Adjusted gross margin before FV adjustments on plant propagation net revenue (1b) 37 % 40 % N/A (3 %) 25 % N/A 12 % Adjusted SG&A expense (1d) $36,687 $31,263 $5,424 17 % $31,351 $5,336 17 % Adjusted EBITDA (1c) $16,678 $19,393 ($2,715) (14 %) $2,319 $14,359 619 % Free cash flow (1e) $2,495 $27,364 ($24,869) (91 %) ($21,866) $24,361 111 % Balance Sheet Working capital (1f) $367,465 $338,741 $28,724 8 % $301,985 $65,480 22 % Cannabis inventory and biological assets (2) $193,980 $212,075 ($18,095) (9 %) $148,112 $45,868 31 % Total assets $852,666 $862,297 ($9,631) (1 %) $838,673 $13,993 2 % (1) These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure: a. Refer to the "Revenue" and "Cost of Sales and Gross Margin" section for a reconciliation of cannabis net revenue to the IFRS equivalent. b. Refer to the "Adjusted Gross Margin" section for reconciliation to the IFRS equivalent. c. Refer to the "Adjusted EBITDA" section for reconciliation to the IFRS equivalent. d. Refer to the "Operating Expenses" section for reconciliation to the IFRS equivalent. e. Refer to the "Liquidity and Capital Resources" section for a reconciliation to the IFRS equivalent. f. "Working capital" is defined as Current Assets less Current Liabilities as reported on the Company's Consolidated Statements of Financial Position. (2) Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets. (3) Certain previously reported amounts have been adjusted to exclude the results of discontinued operations. (4) In connection with the audit of the annual consolidated financial statements as at and for the year ended March 31, 2025, the Company noted that inventory and lease obligation were misstated, impacting the condensed consolidat interim statements filed during the 2025 fiscal balances in the condensed consolidated interim financial statements as at and for the three months ended June 30, 2024, September 30, 2024 and December 31, 2024 were adjusted as a result and the amounts shown above reflect such adjustments. Refer to discussion under "Historical Quarterly Results" section of this MD&A for further detail. Conference Call Aurora will host a conference call today, Wednesday, June 18, 2025, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation. About Aurora Cannabis Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Statements This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding ethe Company's Q4 and full year FY2025 results, statements under the heading "Fiscal Q1 2026 Expectation", including, but not limited to those related to revenue growth and adjusted gross margins, revenue in the plant propagation segment, and expectations for positive adjusted EBITDA and positive free cash flow, statements regarding the Company's continued commitment to strategic growth, operational excellence, and long-term sustained profitability, as well as statements regarding the Company's conference call to discuss results. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the U.S Securities and Exchange Commision's EDGAR ("SEC")\ website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. The Company's annual consolidated financial statements, the MD&A and AIF are available as part of the Company's Annual Report on Form 40-F filed with the SEC and available under the Company's profile on the SEC's website. These documents are also available on the Company's website, and shareholders may receive hard copies of such documents free of charge upon request. Non-GAAP Measures This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the MD&A is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at and on the SEC's EDGAR website at Net Revenue, Adjusted Gross Profit and Margin Net revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows: (1) Net revenue is a Non-GAAP Measure and is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the "Cost of Sales and Gross Margin" section of this MD&A for a reconciliation to IFRS equivalent. (2) Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. Adjusted EBITDA The following is the Company's adjusted EBITDA: (1) Business transformation related charges include costs related to closed facilities, certain IT project costs, costs associated with the repurposing of Sky and Sun, severance and retention costs in connection with the business transformation plan, and costs associated with the retention of certain medical aggregators. Some prior period amounts have been adjusted for changes in presentation. (2) Out-of-period adjustments reflect adjustments to net loss for the financial impact of transactions recorded in the current period that relate to prior periods. Some prior period amounts have been adjusted for changes in presentation. (3) Non-recurring items includes one-time excise tax refunds, non-core adjusted wholesale bulk margins, inventory count adjustments resulting from facility shutdowns and inter-site transfers, litigation and non-recurring project costs. (4) Adjusted EBITDA is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the MD&A. Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs and non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation. (5) Certain previously reported amounts have been adjusted to exclude the results of discontinued operations. (6) In connection with the audit of the annual consolidated financial statements as at and for the year ended March 31, 2025, the Company noted that inventory and lease obligation were misstated, impacting the condensed consolidated interim statements filed during the 2025 fiscal year. Certain balances in the condensed consolidated interim financial statements as at and for the three months ended June 30, 2024, September 30, 2024 and December 31, 2024 were adjusted as a result and the amounts shown above reflect such adjustments. Refer to discussion under "Historical Quarterly Results" section of this MD&A for further detail. Adjusted SG&A Adjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows: (1) Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. (2) Certain previously reported amounts have been adjusted to exclude the results of discontinued operations. (3) In connection with the audit of the annual consolidated financial statements as at and for the year ended March 31, 2025, the Company noted that inventory and lease obligation were misstated, impacting the condensed consolidated interim statements filed during the 2025 fiscal year. Certain balances in the condensed consolidated interim financial statements as at and for the three months ended June 30, 2024, September 30, 2024 and December 31, 2024 were adjusted as a result and the amounts shown above reflect such adjustments. Refer to discussion under "Historical Quarterly Results" section of this MD&A for further detail. Free Cash Flow The table below outlines free cash flow for the periods ended: (1) Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth. (2) Free cash flow is a Non-GAAP Measure and is not a recognized, defined, or a standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. (3) Certain previously reported amounts have been adjusted for a reclassification of restricted cash to cash and cash equivalents as at March 31, 2024, June, 30, 2024, September 30, 2024 and December 31, 2024. Refer to discussion under "Historical Quarterly Results" section of the MD&A for further detail. Working Capital Working capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows: Three months ended ($ thousands) March 31, 2025 December 31, 2024 March 31, 2024 Total current assets 478,328 488,548 426,605 Total current liabilities (110,863) (149,807) (124,620) Working capital (1) 367,465 338,741 301,985 (1) Working capital for the three months ended December 31, 2024 has been adjusted. Refer to discussion under "Liquidity and Capital Resources" section of the MD&A. SOURCE Aurora Cannabis Inc.
